Congenital Heart Disease-Associated Pulmonary Hypertension

Erika B Rosenzweig; Usha Krishnan

doi:10.1016/j.ccm.2020.11.005

Congenital Heart Disease-Associated Pulmonary Hypertension

Clin Chest Med. 2021 Mar;42(1):9-18. doi: 10.1016/j.ccm.2020.11.005. Epub 2021 Jan 12.

Authors

Erika B Rosenzweig¹, Usha Krishnan²

Affiliations

¹ Division of Pediatric Cardiology, Columbia University Irving Medical Center - New York Presbyterian Hospital, 3959 Broadway-CH-2N, New York, NY 10032, USA. Electronic address: esb14@cumc.columbia.edu.
² Division of Pediatric Cardiology, Columbia University Irving Medical Center - New York Presbyterian Hospital, 3959 Broadway-CH-2N, New York, NY 10032, USA.

PMID: 33541620
DOI: 10.1016/j.ccm.2020.11.005

Abstract

Presently, with increasing survival of patients with congenital heart disease (CHD), pulmonary arterial hypertension (PAH) associated with CHD is commonly encountered in children and adults. This increased prevalence is seen despite significant advances in early diagnosis and surgical correction of patients with structural CHD. PAH is the cause of significant morbidity and mortality in these patients and comes in many forms. With the increased availability of targeted therapies for PAH, there is hope for improved hemodynamics, exercise capacity, quality of life, and possibly survival for these patients. There may also be opportunities for combined medical and interventional/surgical approaches for some.

Keywords: Congenital heart disease; Eisenmenger syndrome; Pulmonary arterial hypertension; Pulmonary vascular disease.

Publication types

Review

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Exercise*
Heart Defects, Congenital / complications*
Hemodynamics*
Humans
Hypertension, Pulmonary* / epidemiology
Hypertension, Pulmonary* / etiology
Hypertension, Pulmonary* / surgery
Hypertension, Pulmonary* / therapy
Longevity
Middle Aged
Patients
Quality of Life*
Young Adult